Recurring revenue, monopolistic market positions, and returns that tend to beat even the risky biotechs tie these three together.
News & Analysis: Abiomed
Find out why these stocks missed a rally on Wall Street.
Worldwide demand for temporary heart pumps continues to soar.
ABMD earnings call for the period ending December 31, 2018.
Some of the best gains last year came from unexpected companies.
This fast-growing and profitable maker of heart pumps appears to still have a long runway for growth ahead.
These healthcare stocks crushed the S&P 500's return last year, but that doesn't guarantee they'll be top performers in 2019.
Which of these medical device titans is the better choice for new money today?
All three of these businesses promise massive growth, but are any of them worth buying?
You could miss out on market-beating returns if you don't have these top stocks in your portfolio.